Search

Angela A. Armstrong

Examiner (ID: 7226, Phone: (571)272-7598 , Office: P/2659 )

Most Active Art Unit
2659
Art Unit(s)
2659, 2641, 2741, 2654, 2626
Total Applications
1003
Issued Applications
675
Pending Applications
123
Abandoned Applications
230

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 16198622 [patent_doc_number] => 10723772 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-28 [patent_title] => Follistatin in treating duchenne muscular dystrophy [patent_app_type] => utility [patent_app_number] => 15/951929 [patent_app_country] => US [patent_app_date] => 2018-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 20987 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15951929 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/951929
Follistatin in treating duchenne muscular dystrophy Apr 11, 2018 Issued
Array ( [id] => 16718575 [patent_doc_number] => 20210085722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => DOUBLE GENE-MODIFIED STEM CELL AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/954763 [patent_app_country] => US [patent_app_date] => 2018-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12680 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16954763 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/954763
FGF21 and GLP1 double gene-modified mesenchymal stem cell and use in treating a metabolic disease Apr 1, 2018 Issued
Array ( [id] => 16748830 [patent_doc_number] => 20210100839 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-08 [patent_title] => NEW UNIVERSAL CHIMERIC ANTIGEN RECEPTOR T CELLS SPECIFIC FOR CD22 [patent_app_type] => utility [patent_app_number] => 16/498276 [patent_app_country] => US [patent_app_date] => 2018-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49834 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498276 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/498276
Universal chimeric antigen receptor T cells specific for CD22 Mar 29, 2018 Issued
Array ( [id] => 13342857 [patent_doc_number] => 20180222968 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => ANTIBODY THAT BINDS MURINE WISE PROTEIN [patent_app_type] => utility [patent_app_number] => 15/942007 [patent_app_country] => US [patent_app_date] => 2018-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11211 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15942007 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/942007
ANTIBODY THAT BINDS MURINE WISE PROTEIN Mar 29, 2018 Abandoned
Array ( [id] => 16012765 [patent_doc_number] => 20200181225 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => ENGINEERED T-CELL MODULATING MOLECULES AND METHODS OF USING SAME [patent_app_type] => utility [patent_app_number] => 16/498586 [patent_app_country] => US [patent_app_date] => 2018-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19971 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498586 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/498586
ENGINEERED T-CELL MODULATING MOLECULES AND METHODS OF USING SAME Mar 27, 2018 Abandoned
Array ( [id] => 17060150 [patent_doc_number] => 11104737 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => ACVR2A-specific antibody and method of treatment of muscle atrophy [patent_app_type] => utility [patent_app_number] => 16/488082 [patent_app_country] => US [patent_app_date] => 2018-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65783 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16488082 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/488082
ACVR2A-specific antibody and method of treatment of muscle atrophy Mar 26, 2018 Issued
Array ( [id] => 17922847 [patent_doc_number] => 11466080 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-11 [patent_title] => Methods of treating cancer using anti-LRP1 polyclonal antibodies [patent_app_type] => utility [patent_app_number] => 16/496129 [patent_app_country] => US [patent_app_date] => 2018-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 26 [patent_no_of_words] => 13461 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16496129 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/496129
Methods of treating cancer using anti-LRP1 polyclonal antibodies Mar 21, 2018 Issued
Array ( [id] => 17556093 [patent_doc_number] => 11312769 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-26 [patent_title] => Anti-TMEFF1 antibodies and antibody drug conjugates [patent_app_type] => utility [patent_app_number] => 16/495633 [patent_app_country] => US [patent_app_date] => 2018-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 30 [patent_no_of_words] => 54714 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 217 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16495633 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/495633
Anti-TMEFF1 antibodies and antibody drug conjugates Mar 21, 2018 Issued
Array ( [id] => 19519866 [patent_doc_number] => 12121564 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-22 [patent_title] => Use of lambda interferons in the treatment of obesity-related disorders and related diseases [patent_app_type] => utility [patent_app_number] => 16/604378 [patent_app_country] => US [patent_app_date] => 2018-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 19 [patent_no_of_words] => 21052 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604378 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/604378
Use of lambda interferons in the treatment of obesity-related disorders and related diseases Mar 15, 2018 Issued
Array ( [id] => 15646701 [patent_doc_number] => 20200085880 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => METHODS AND COMPOSITIONS FOR ENHANCING CARDIOMYOCYTE MATURATION AND ENGRAFTMENT [patent_app_type] => utility [patent_app_number] => 16/493888 [patent_app_country] => US [patent_app_date] => 2018-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29961 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16493888 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/493888
Methods and compositions for enhancing cardiomyocyte maturation and engraftment Mar 14, 2018 Issued
Array ( [id] => 17377040 [patent_doc_number] => 11235029 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-01 [patent_title] => Methods for treating heart failure with a TRKB agonist [patent_app_type] => utility [patent_app_number] => 15/916494 [patent_app_country] => US [patent_app_date] => 2018-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 15 [patent_no_of_words] => 27030 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15916494 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/916494
Methods for treating heart failure with a TRKB agonist Mar 8, 2018 Issued
Array ( [id] => 13413287 [patent_doc_number] => 20180258186 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => NME Inhibitors and Methods of Using NME Inhibitors [patent_app_type] => utility [patent_app_number] => 15/910894 [patent_app_country] => US [patent_app_date] => 2018-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28480 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15910894 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/910894
NME Inhibitors and Methods of Using NME Inhibitors Mar 1, 2018 Abandoned
Array ( [id] => 17497608 [patent_doc_number] => 11286301 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-29 [patent_title] => Antifibrotic activity of CD47 blockade [patent_app_type] => utility [patent_app_number] => 16/487051 [patent_app_country] => US [patent_app_date] => 2018-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 49 [patent_figures_cnt] => 75 [patent_no_of_words] => 21412 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16487051 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/487051
Antifibrotic activity of CD47 blockade Feb 27, 2018 Issued
Array ( [id] => 17089787 [patent_doc_number] => 11117964 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-14 [patent_title] => Anti-KIR3DL1 antibodies [patent_app_type] => utility [patent_app_number] => 16/484451 [patent_app_country] => US [patent_app_date] => 2018-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 26333 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 403 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16484451 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/484451
Anti-KIR3DL1 antibodies Feb 25, 2018 Issued
Array ( [id] => 17921636 [patent_doc_number] => 11464857 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-11 [patent_title] => Low-viscosity, high concentration evolocumab formulations and methods of making the same [patent_app_type] => utility [patent_app_number] => 15/902775 [patent_app_country] => US [patent_app_date] => 2018-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 75 [patent_no_of_words] => 43391 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 200 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15902775 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/902775
Low-viscosity, high concentration evolocumab formulations and methods of making the same Feb 21, 2018 Issued
Array ( [id] => 13524567 [patent_doc_number] => 20180313826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => BIOMARKER FOR CORONARY ARTERY DISEASE [patent_app_type] => utility [patent_app_number] => 15/900680 [patent_app_country] => US [patent_app_date] => 2018-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21075 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15900680 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/900680
Circulating antibodies against MAA adducts as biomarker for coronary artery disease Feb 19, 2018 Issued
Array ( [id] => 16009335 [patent_doc_number] => 20200179510 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5 INHIBITION SUPPRESSES TUMOR FORMATION [patent_app_type] => utility [patent_app_number] => 16/496252 [patent_app_country] => US [patent_app_date] => 2018-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27168 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16496252 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/496252
LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5 INHIBITION SUPPRESSES TUMOR FORMATION Feb 15, 2018 Abandoned
Array ( [id] => 12842494 [patent_doc_number] => 20180172671 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-21 [patent_title] => METHODS FOR TREATING NEURAL CELL SWELLING [patent_app_type] => utility [patent_app_number] => 15/895945 [patent_app_country] => US [patent_app_date] => 2018-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21550 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15895945 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/895945
METHODS FOR TREATING NEURAL CELL SWELLING Feb 12, 2018 Abandoned
Array ( [id] => 15649689 [patent_doc_number] => 20200087374 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => INTERACTION BETWEEN C-PEPTIDES AND ELASTIN RECEPTOR, A MODEL FOR UNDERSTANDING VASCULAR DISEASE [patent_app_type] => utility [patent_app_number] => 16/483717 [patent_app_country] => US [patent_app_date] => 2018-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50296 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16483717 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/483717
INTERACTION BETWEEN C-PEPTIDES AND ELASTIN RECEPTOR, A MODEL FOR UNDERSTANDING VASCULAR DISEASE Feb 4, 2018 Abandoned
Array ( [id] => 15649675 [patent_doc_number] => 20200087367 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE [patent_app_type] => utility [patent_app_number] => 16/482883 [patent_app_country] => US [patent_app_date] => 2018-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68098 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -123 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16482883 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/482883
COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE Feb 4, 2018 Abandoned
Menu